Nasdaq · Healthcare

Sight Sciences, Inc. (SGHT)

As-reported financials and recent SEC filings for Sight Sciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$77.4M

Net income

$-38.4M

Net margin

-49.7%

Diluted EPS

$-0.74

ROE

-60.1%

P/E (TTM)

—

Market cap

—

Debt / equity

0.6×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$77.4M	$79.9M	$81.1M	$71.3M	$49.0M
Gross profit	$66.7M	$68.3M	$69.2M	$59.0M	$40.3M
Operating income	$-37.1M	$-50.5M	$-57.3M	$-84.0M	$-51.5M
Net income	$-38.4M	$-51.5M	$-55.5M	$-86.2M	$-63.0M
Diluted EPS	$-0.74	$-1.03	$-1.14	$-1.80	$-2.36

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

1442026-07-06

1442026-07-06

42026-07-06

42026-07-06

42026-07-06

42026-07-06

42026-07-06

42026-07-06

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on SGHT

Search Sight Sciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.